146 related articles for article (PubMed ID: 9226169)
1. High molecular weight kininogen peptides inhibit the formation of kallikrein on endothelial cell surfaces and subsequent urokinase-dependent plasmin formation.
Lin Y; Harris RB; Yan W; McCrae KR; Zhang H; Colman RW
Blood; 1997 Jul; 90(2):690-7. PubMed ID: 9226169
[TBL] [Abstract][Full Text] [Related]
2. Physical and biological significance of peptide sequences mediating the interaction between high molecular weight kininogen and plasma prekallikrein.
Colman RW; Lin Y; Yan WY; McCrae KR; Shenoy SS; Harris RB
Immunopharmacology; 1997 Jun; 36(2-3):193-200. PubMed ID: 9228546
[TBL] [Abstract][Full Text] [Related]
3. The carboxyl terminus of bradykinin and amino terminus of the light chain of kininogens comprise an endothelial cell binding domain.
Hasan AA; Cines DB; Zhang J; Schmaier AH
J Biol Chem; 1994 Dec; 269(50):31822-30. PubMed ID: 7989355
[TBL] [Abstract][Full Text] [Related]
4. Mapping binding domains of kininogens on endothelial cell cytokeratin 1.
Shariat-Madar Z; Mahdi F; Schmaier AH
J Biol Chem; 1999 Mar; 274(11):7137-45. PubMed ID: 10066772
[TBL] [Abstract][Full Text] [Related]
5. Human high molecular weight kininogen binds to human umbilical vein endothelial cells via its heavy and light chains.
Reddigari SR; Kuna P; Miragliotta G; Shibayama Y; Nishikawa K; Kaplan AP
Blood; 1993 Mar; 81(5):1306-11. PubMed ID: 8443392
[TBL] [Abstract][Full Text] [Related]
6. High molecular weight kininogen binds to platelets by its heavy and light chains and when bound has altered susceptibility to kallikrein cleavage.
Meloni FJ; Gustafson EJ; Schmaier AH
Blood; 1992 Mar; 79(5):1233-44. PubMed ID: 1536948
[TBL] [Abstract][Full Text] [Related]
7. High molecular weight kininogen regulates prekallikrein assembly and activation on endothelial cells: a novel mechanism for contact activation.
Motta G; Rojkjaer R; Hasan AA; Cines DB; Schmaier AH
Blood; 1998 Jan; 91(2):516-28. PubMed ID: 9427705
[TBL] [Abstract][Full Text] [Related]
8. Generation of vasoactive peptide bradykinin from human umbilical vein endothelium-bound high molecular weight kininogen by plasma kallikrein.
Nishikawa K; Shibayama Y; Kuna P; Calcaterra E; Kaplan AP; Reddigari SR
Blood; 1992 Oct; 80(8):1980-8. PubMed ID: 1391955
[TBL] [Abstract][Full Text] [Related]
9. Cytokine and estrogen stimulation of endothelial cells augments activation of the prekallikrein-high molecular weight kininogen complex: Implications for hereditary angioedema.
Joseph K; Tholanikunnel BG; Kaplan AP
J Allergy Clin Immunol; 2017 Jul; 140(1):170-176. PubMed ID: 27826093
[TBL] [Abstract][Full Text] [Related]
10. Localization of the binding site on plasma kallikrein for high-molecular-weight kininogen to both apple 1 and apple 4 domains of the heavy chain.
Page JD; You JL; Harris RB; Colman RW
Arch Biochem Biophys; 1994 Oct; 314(1):159-64. PubMed ID: 7944388
[TBL] [Abstract][Full Text] [Related]
11. Domain 5 of high molecular weight kininogen (kininostatin) down-regulates endothelial cell proliferation and migration and inhibits angiogenesis.
Colman RW; Jameson BA; Lin Y; Johnson D; Mousa SA
Blood; 2000 Jan; 95(2):543-50. PubMed ID: 10627460
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of contact activation by a kininogen peptide (HKH20) derived from domain 5.
Nakazawa Y; Joseph K; Kaplan AP
Int Immunopharmacol; 2002 Dec; 2(13-14):1875-85. PubMed ID: 12494915
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal antibody to human high-molecular-weight kininogen recognizes its prekallikrein binding site and inhibits its coagulant activity.
Reddigari SR; Kaplan AP
Blood; 1989 Aug; 74(2):695-702. PubMed ID: 2752143
[TBL] [Abstract][Full Text] [Related]
14. Assembly of high molecular weight kininogen and activation of prekallikrein on cell matrix.
Motta G; Shariat-Madar Z; Mahdi F; Sampaio CA; Schmaier AH
Thromb Haemost; 2001 Sep; 86(3):840-7. PubMed ID: 11583317
[TBL] [Abstract][Full Text] [Related]
15. Parallel mechanisms of high molecular weight kininogen action as a cofactor in kallikrein inactivation and prekallikrein activation reactions.
Olson ST; Francis AM; Sheffer R; Choay J
Biochemistry; 1993 Nov; 32(45):12148-59. PubMed ID: 8218292
[TBL] [Abstract][Full Text] [Related]
16. Direct evidence for multifacial contacts between high molecular weight kininogen and plasma prekallikrein.
Lin Y; Shenoy SS; Harris RB; Colman RW
Biochemistry; 1996 Oct; 35(39):12945-9. PubMed ID: 8841140
[TBL] [Abstract][Full Text] [Related]
17. Binding of high molecular weight kininogen to human endothelial cells is mediated via a site within domains 2 and 3 of the urokinase receptor.
Colman RW; Pixley RA; Najamunnisa S; Yan W; Wang J; Mazar A; McCrae KR
J Clin Invest; 1997 Sep; 100(6):1481-7. PubMed ID: 9294114
[TBL] [Abstract][Full Text] [Related]
18. Assembly and activation of the intrinsic fibrinolytic pathway on the surface of human endothelial cells in culture.
Lenich C; Pannell R; Gurewich V
Thromb Haemost; 1995 Aug; 74(2):698-703. PubMed ID: 8585009
[TBL] [Abstract][Full Text] [Related]
19. Localization of distinct functional domains on prekallikrein for interaction with both high molecular weight kininogen and activated factor XII in a 28-kDa fragment (amino acids 141-371).
Page JD; Colman RW
J Biol Chem; 1991 May; 266(13):8143-8. PubMed ID: 1708772
[TBL] [Abstract][Full Text] [Related]
20. Assembly and activation of HK-PK complex on endothelial cells results in bradykinin liberation and NO formation.
Zhao Y; Qiu Q; Mahdi F; Shariat-Madar Z; Røjkjaer R; Schmaier AH
Am J Physiol Heart Circ Physiol; 2001 Apr; 280(4):H1821-9. PubMed ID: 11247797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
